These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17487387)

  • 1. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
    Takao M; Okamoto A; Nikaido T; Urashima M; Takakura S; Saito M; Saito M; Okamoto S; Takikawa O; Sasaki H; Yasuda M; Ochiai K; Tanaka T
    Oncol Rep; 2007 Jun; 17(6):1333-9. PubMed ID: 17487387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
    Ino K; Yoshida N; Kajiyama H; Shibata K; Yamamoto E; Kidokoro K; Takahashi N; Terauchi M; Nawa A; Nomura S; Nagasaka T; Takikawa O; Kikkawa F
    Br J Cancer; 2006 Dec; 95(11):1555-61. PubMed ID: 17117179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival.
    Ino K; Yamamoto E; Shibata K; Kajiyama H; Yoshida N; Terauchi M; Nawa A; Nagasaka T; Takikawa O; Kikkawa F
    Clin Cancer Res; 2008 Apr; 14(8):2310-7. PubMed ID: 18413819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
    Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
    J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer].
    Sakurai K; Amano S; Enomoto K; Kashio M; Saito Y; Sakamoto A; Matsuo S; Suzuki M; Kitajima A; Hirano T; Negishi N
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1546-9. PubMed ID: 16315864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
    Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
    Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary.
    Terauchi F; Okamoto A; Nagashima T; Kobayashi Y; Moritake T; Yamamoto Y; Takakura S; Iwaki S; Ogura H
    Oncol Rep; 2005 Aug; 14(2):363-8. PubMed ID: 16012716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
    Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
    Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
    Kritpracha K; Hanprasertpong J; Chandeying V; Dechsukhum C; Geater A
    J Obstet Gynaecol Res; 2005 Jun; 31(3):268-76. PubMed ID: 15916666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
    Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
    Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
    APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of glutathione S-transferase-pi in operative specimens as marker of chemoresistance in patients with ovarian cancer].
    Huang J; Gu M; Chen C
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):458-61. PubMed ID: 9639737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase 2 expression in serous tumors of the ovary.
    Singhal PK; Spiegel G; Driscoll D; Odunsi K; Lele S; Rodabaugh KJ
    Int J Gynecol Pathol; 2005 Jan; 24(1):62-6. PubMed ID: 15626918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of 91 cases of hereditary breast and ovarian cancer].
    Li N; Wu LY; Zhang R; Zhang X; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):245-7. PubMed ID: 15949430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.